Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI

#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt

Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking! POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o

↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx. Adjusted on smoking status, age and BMI. Shall we follow this group of patients more closely? OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k

🔜 Remission in PsA : the earlier the better ⏰ Dutch cohort (DEPAR) 300+pts Failure to achieve MDA 1yr post diagnosis 🧨worst QoL yr 1️⃣2️⃣&3️⃣ 🧨↗️bioDMARDs use over time 🧨no recovery #OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP

PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF. PMR is now far from just a vibe - real science, real targets for therapy. Not every day that PMR basic science makes it on stage, lovely from @VasculitisUMCG @jiemy_william #EULAR2022 @RheumNow https://t.co/zem3JEosQL

Retrospective nation-wide italian study: Long term exposure to : 🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases 🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2 OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW

Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070 RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz

EULAR 2022 Featured Industry Abstracts Review is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here. https://t.co/ggnAyuvAbl https://t.co/WjKDb70RkW

#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found: 💠32% had a flare (new IS or Pred>9mg/d) 💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC

#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those: 💠SLEDAI=>10 💠dsDNA+ve + ⬇️C3 and/ ⬇️C4 💠⬇️C3 and/ C4 pre-treatment 💠Response high regardless SDI, Steroid, #lupus duration @RheumNow https://t.co/fLggazbRQu